FY2027 EPS Estimates for Astrazeneca Cut by Erste Group Bank

Astrazeneca Plc (NYSE:AZN) – Analysts at Erste Group Bank reduced their FY2027 earnings per share estimates for Astrazeneca in a report released on Wednesday, August 5th. Erste Group Bank analyst H. Engel now expects that the company will earn $11.42 per share for the year, down from their prior forecast of $11.50. The consensus estimate for Astrazeneca’s current full-year earnings is $10.21 per share.

A number of other equities analysts have also commented on the company. HSBC lowered Astrazeneca from a “buy” rating to a “hold” rating in a research note on Monday, July 13th. Barclays restated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Weiss Ratings downgraded shares of Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, July 28th. Wall Street Zen lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Bank of America reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Twelve investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $211.00.

Astrazeneca Trading Down 2.0%

Shares of AZN stock opened at $158.68 on Monday. The stock has a market cap of $246.10 billion, a price-to-earnings ratio of 23.72, a PEG ratio of 1.40 and a beta of 0.26. The stock has a 50-day moving average of $175.61 and a 200-day moving average of $186.81. The company has a current ratio of 0.89, a quick ratio of 0.67 and a debt-to-equity ratio of 0.47. Astrazeneca has a 1-year low of $145.79 and a 1-year high of $212.71.

Astrazeneca (NYSE:AZN) last announced its earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, topping the consensus estimate of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The firm had revenue of $15.38 billion for the quarter, compared to the consensus estimate of $15.44 billion. During the same period in the previous year, the business earned $2.17 EPS. The business’s quarterly revenue was up 6.4% compared to the same quarter last year.

Institutional Investors Weigh In On Astrazeneca

Hedge funds have recently added to or reduced their stakes in the business. Mascoma Wealth Management LLC acquired a new stake in shares of Astrazeneca during the 1st quarter worth approximately $26,000. MV Capital Management Inc. acquired a new position in shares of Astrazeneca during the 4th quarter valued at $26,000. Roxbury Financial LLC acquired a new position in shares of Astrazeneca during the 2nd quarter valued at $29,000. Reflection Asset Management bought a new position in Astrazeneca during the fourth quarter worth $31,000. Finally, Resources Management Corp CT ADV bought a new position in Astrazeneca during the first quarter worth $35,000. 20.35% of the stock is currently owned by institutional investors.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.